Adenovirus-based vaccines - a platform for pandemic preparedness against emerging viral pathogens.
MetadataShow full item record
AbstractZoonotic viruses continually pose a pandemic threat. Infection of humans with viruses for which we typically have little or no prior immunity, can result in epidemics with high morbidity and mortality. These epidemics can have public health and economic impact, and can exacerbate civil unrest or political instability. Changes in human behavior in the past few decades: increased global travel, farming intensification, the exotic animal trade, as well as the impact of global warming on animal migratory patterns, habitats and ecosystems, contribute to the increased frequency of cross-species transmission events. Investing in the pre-clinical advancement of vaccine candidates against diverse emerging viral threats is crucial for pandemic preparedness. Replication-defective adenoviral (Ad) vectors have demonstrated their utility as an outbreak-responsive vaccine platform during the SARS-CoV-2 pandemic. Ad vectors are easy to engineer, are amenable to rapid, inexpensive manufacturing, are relatively safe and immunogenic in humans, and importantly, and do not require specialized cold-chain storage, making them an ideal platform for equitable global distribution, or stockpiling. In this review, we discuss the progress in applying Ad-based vaccines against emerging viruses, and summarize their global safety profile, as reflected by their widespread geographic use during the SARS-CoV-2 pandemic.
Rights/TermsCopyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17846